8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 28, 2026·SEC
Genprex, Inc.(GNPX)Earnings, Financials & Key Ratios
GNPX•NASDAQ
Price updated Jun 19, 2026
AboutGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Show more
- Revenue$0
- EBITDA-$15M+26.8%
- Net Income-$16M+23.1%
- EPS (Diluted)-17.40+93.5%
- ROE-338.74%+27.5%
GNPX Key Insights
Genprex, Inc. (GNPX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GNPX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GNPX Price & Volume
Genprex, Inc. (GNPX) stock price & volume — 10-year historical chart
Loading chart...
GNPX Growth Metrics
Genprex, Inc. (GNPX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM12.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM93.77%
Return on Capital
10 Years-241.62%
5 Years-226.66%
3 Years-333.68%
Last Year-323.09%
GNPX Recent Earnings
Genprex, Inc. (GNPX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (36%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.64
—
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$1.15+91.2%
$13.00
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$5.00+60.0%
$12.50
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$8.50+59.5%
$21.00
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.64 | — |
| Q2 2026 | Mar 30, 2026 | $1.15vs $13.00+91.2% | — |
| Q4 2025 | Nov 14, 2025 | $5.00vs $12.50+60.0% | — |
| Q3 2025 | Aug 14, 2025 | $8.50vs $21.00+59.5% | — |
Based on last 12 quarters of dataView full earnings history →
GNPX Peer Comparison
Genprex, Inc. (GNPX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 CLRB | 8.91M | 2.79 | -0.33 | -264.79% | 0.04 | |||
 SNDX | 1.68B | 19.00 | -5.78 | 6.28% | -112.01% | -256.66% | 5.36 |
Compare GNPX vs Peers
Genprex, Inc. (GNPX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GNPX Income Statement
Genprex, Inc. (GNPX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 5.88K | 13.07K | 22.78K | 22.53K | 25.57K | 15K | 6.69K | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | -5.88K▲ 0% | -13.07K▼ 122.1% | -22.78K▼ 74.3% | -22.53K▲ 1.1% | -25.57K▼ 13.5% | -15K▲ 41.3% | -6.69K▲ 55.4% | 0▲ 100.0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | -122.09% | -74.27% | 1.07% | -13.5% | 41.33% | 55.39% | 100% | - |
Operating Expenses | 3.31M | 12.36M | 10.67M | 17.94M | 20.65M | 23.81M | 31.06M | 21.17M | 15.52M | 16.04M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 3.02M | 11.39M | 8.7M | 10.64M | 11.68M | 12.3M | 13.44M | 10.63M | 6.09M | 6.41M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 289.93K | 971.43K | 1.97M | 7.3M | 8.97M | 11.51M | 17.62M | 10.54M | 9.43M | 9.63M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 3.24K | 5.88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -3.31M▲ 0% | -12.36M▼ 273.3% | -10.68M▲ 13.6% | -17.96M▼ 68.1% | -20.67M▼ 15.1% | -23.83M▼ 15.3% | -31.08M▼ 30.4% | -21.17M▲ 31.9% | -15.52M▲ 26.7% | -16.04M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 19.84% | -273.26% | 13.6% | -68.14% | -15.08% | -15.29% | -30.4% | 31.86% | 26.72% | - |
EBITDA | -3.31M | -12.36M | -10.67M | -17.94M | -20.65M | -23.81M | -31.06M | -21.17M | -15.49M | -16.02M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 19.9% | -273.44% | 13.66% | -68.13% | -15.1% | -15.29% | -30.48% | 31.85% | 26.83% | 16.29% |
D&A (Non-Cash Add-back) | 3.24K | 5.88K | 13.07K | 22.78K | 22.53K | 25.57K | 15K | 6.69K | 0 | 1.67K |
EBIT | -3.31M | -12.33M | -10.65M | -17.94M | -20.66M | -23.74M | -31.08M | -21.11M | -15.49M | -16.03M |
Net Interest Income | -1.81K | -8.8K | 27.91K | 18.81K | 5.13K | 90.1K | 215.11K | 63.57K | -739.93K | -430.98K |
Interest Income | 80 | 29.18K | 27.91K | 18.81K | 5.13K | 90.1K | 215.11K | 63.57K | 0 | 24.57K |
Interest Expense | 1.89K | 37.98K | 0 | 0 | 0 | 0 | 0 | 0 | 739.93K | 455.55K |
Other Income/Expense | -1.81K | -8.8K | 27.91K | 18.81K | 5.13K | 90.1K | 215.11K | 63K | -713.33K | -685.74K |
Pretax Income | -3.31M▲ 0% | -12.37M▼ 273.3% | -10.65M▲ 13.9% | -17.94M▼ 68.4% | -20.66M▼ 15.2% | -23.74M▼ 14.9% | -30.86M▼ 30.0% | -21.11M▲ 31.6% | -16.23M▲ 23.1% | -16.73M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 80 | 29.18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0% | -0.24% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.31M▲ 0% | -12.37M▼ 273.3% | -10.65M▲ 13.9% | -17.94M▼ 68.4% | -20.66M▼ 15.2% | -23.74M▼ 14.9% | -30.86M▼ 30.0% | -21.11M▲ 31.6% | -16.23M▲ 23.1% | -16.73M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 19.8% | -273.32% | 13.88% | -68.4% | -15.17% | -14.88% | -29.99% | 31.59% | 23.13% | 12.46% |
Net Income (Continuing) | -3.31M | -12.37M | -10.65M | -17.94M | -20.66M | -23.74M | -30.86M | -21.11M | -16.23M | -16.73M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -576.50▲ 0% | -1797.00▼ 211.7% | -1329.50▲ 26.0% | -1009.00▲ 24.1% | -877.50▲ 13.0% | -990.00▼ 12.8% | -1128.00▼ 13.9% | -266.95▲ 76.3% | -17.40▲ 93.5% | -2.41▲ 0% |
EPS Growth % | 24.44% | -211.71% | 26.02% | 24.11% | 13.03% | -12.82% | -13.94% | 76.33% | 93.48% | 93.77% |
EPS (Basic) | -577.50 | -1798.50 | -1332.00 | -1009.00 | -877.50 | -990.00 | -1129.00 | -266.95 | -17.40 | - |
Diluted Shares Outstanding | 5.75K | 6.89K | 8.01K | 17.76K | 23.55K | 23.98K | 27.36K | 80.12K | 932.73K | 6.95M |
Basic Shares Outstanding | 5.74K | 6.88K | 8K | 17.76K | 23.54K | 23.96K | 27.34K | 80.12K | 932.73K | 6.95M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GNPX Balance Sheet
Genprex, Inc. (GNPX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 193.57K | 8.85M | 2.98M | 30.72M | 39.14M | 21.47M | 7.53M | 2.08M | 8.36M | 18.8M |
Cash & Short-Term Investments | 161.25K | 8.6M | 2M | 27.32M | 38.63M | 20.95M | 6.74M | 1.6M | 7.83M | 18.05M |
Cash Only | 161.25K | 8.6M | 2M | 27.32M | 38.63M | 20.95M | 6.74M | 1.6M | 7.83M | 18.05M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 9.3K | 655 | 127 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 801.78K | 3.01M | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | 22.39K | 48.25K | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 34.85K | 794.14K | 475.81K | 525.93K | 753.8K |
Total Non-Current Assets | 1.07M | 421.89K | 557.59K | 651.81K | 3.72M | 3.61M | 3.14M | 2.05M | 1.8M | 1.5M |
Property, Plant & Equipment | 7.8K | 24.35K | 44.65K | 39.44K | 48.61K | 23.03K | 7.86K | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 298.57K | 379.45K | 491.2K | 601.63K | 642.36K | 702.1K | 773.48K | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 759.59K | 18.09K | 21.73K | 10.74K | 3.03M | 2.89M | 2.36M | 2.05M | 1.8M | 1.5M |
Total Assets | 1.26M▲ 0% | 9.27M▲ 635.9% | 3.53M▼ 61.9% | 31.37M▲ 787.5% | 42.86M▲ 36.6% | 25.09M▼ 41.5% | 10.67M▼ 57.5% | 4.12M▼ 61.3% | 10.16M▲ 146.3% | 20.31M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -34.07% | 635.9% | -61.87% | 787.53% | 36.65% | -41.48% | -57.46% | -61.35% | 146.32% | 333.34% |
Total Current Liabilities | 830.96K | 387.82K | 510.68K | 450.72K | 1.59M | 2.81M | 3.25M | 2.5M | 2.17M | 3.35M |
Accounts Payable | 629.07K | 295.07K | 436.26K | 192.97K | 973.2K | 442.93K | 1.4M | 1.07M | 743.07K | 1.66M |
Days Payables Outstanding | - | 18.3K | 12.18K | 3.09K | 15.76K | 6.32K | 34K | 58.59K | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 201.89K | 92.75K | 74.43K | 257.76K | 612.1K | 2.37M | 1.86M | 1.43M | 1.43M | 1.7M |
Current Ratio | 0.23x | 22.81x | 5.83x | 68.15x | 24.69x | 7.64x | 2.31x | 0.83x | 3.84x | 5.61x |
Quick Ratio | 0.23x | 22.81x | 4.26x | 61.47x | 24.69x | 7.64x | 2.31x | 0.83x | 3.84x | 5.61x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22.5K | 22.5K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22.5K | 22.5K |
Total Liabilities | 830.96K | 387.82K | 510.68K | 450.72K | 1.59M | 2.81M | 3.25M | 2.5M | 2.2M | 3.38M |
Total Debt | 201.89K | 92.75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | 40.64K | -8.51M | -2M | -27.32M | -38.63M | -20.95M | -6.74M | -1.6M | -7.83M | -18.05M |
Debt / Equity | 0.47x | 0.01x | - | - | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.13x |
Interest Coverage | -1752.56x | -324.74x | - | - | - | - | - | - | -20.93x | -35.18x |
Total Equity | 428.57K▲ 0% | 8.88M▲ 1972.3% | 3.02M▼ 66.0% | 30.92M▲ 922.5% | 41.28M▲ 33.5% | 22.27M▼ 46.0% | 7.42M▼ 66.7% | 1.62M▼ 78.2% | 7.96M▲ 391.4% | 16.93M▲ 0% |
Equity Growth % | -73.62% | 1972.25% | -65.96% | 922.52% | 33.51% | -46.04% | -66.7% | -78.15% | 391.43% | 607.27% |
Book Value per Share | 74.53 | 1289.74 | 377.28 | 1740.70 | 1752.81 | 929.00 | 271.12 | 20.22 | 8.54 | 2.44 |
Total Shareholders' Equity | 428.57K | 8.88M | 3.02M | 30.92M | 41.28M | 22.27M | 7.42M | 1.62M | 7.96M | 16.93M |
Common Stock | 11.72K | 15.24K | 19.26K | 43.12K | 47.87K | 1.2K | 1.49K | 10.86K | 3.29K | 9.04K |
Retained Earnings | -17.45M | -29.82M | -40.48M | -58.42M | -79.09M | -102.83M | -133.69M | -154.8M | -171.03M | -175.49M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GNPX Cash Flow Statement
Genprex, Inc. (GNPX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.17M | -6.85M | -6.92M | -13.94M | -14.28M | -17.78M | -24.74M | -17.15M | -15.31M | -14.29M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -73.97% | -215.28% | -1.05% | -101.41% | -2.51% | -24.46% | -39.15% | 30.68% | 10.72% | -73.66% |
Net Income | -3.31M | -12.37M | -10.65M | -17.94M | -19.59M | -23.74M | -30.86M | -21.11M | -16.23M | -16.73M |
Depreciation & Amortization | 3.24K | 5.88K | 13.07K | 22.78K | 22.53K | 25.57K | 15K | 6.69K | 0 | 0 |
Stock-Based Compensation | 1.32M | 5.44M | 3.53M | 4.25M | 5.35M | 4.73M | 5.41M | 3.3M | 312.83K | 128.64K |
Deferred Taxes | 0 | 0 | -3.41M | -4.54M | -4.61M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 545 | 5.45M | 3.41M | 4.54M | 3.54M | 0 | 0 | 773.48K | 739.93K | 813.37K |
Working Capital Changes | -184.57K | 84.54K | 192.99K | -261.28K | 1.01M | 1.2M | 698.13K | -121.08K | -135.03K | 1.5M |
Change in Receivables | -663 | -453 | 8.64K | 528 | 127 | -34.85K | 34.85K | 0 | 0 | 0 |
Change in Inventory | 0 | -231.46K | 46.81K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | -443.14K | 141.19K | -247.29K | 780.23K | -530.27K | 954.69K | -323.31K | -331.23K | 129.34K |
Cash from Investing | -63.42K | -103.32K | -946.9K | -2.34M | -83.8K | 97.73K | -71.21K | 1.17K | 0 | 0 |
Capital Expenditures | -63.42K | -103.32K | -946.9K | -2.34M | -83.8K | -59.73K | -71.38K | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -58 | -81 | 0 | 0 | 0 | 157.47K | 169 | 1.17K | 0 | 0 |
Cash from Financing | 793.97K | 15.39M | 1.27M | 41.59M | 25.68M | 6.43K | 10.59M | 12.01M | 21.54M | 28.87M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 793.97K | 15.39M | 1.27M | 41.59M | 25.68M | 6.43K | 10.59M | 12.01M | 21.54M | 28.87M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -277.12M | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 277.12M | 0 | 0 |
Net Change in Cash | -1.44M▲ 0% | 8.44M▲ 685.7% | -6.6M▼ 178.2% | 25.32M▲ 483.7% | 11.31M▼ 55.3% | -17.67M▼ 256.3% | -14.22M▲ 19.6% | -5.14M▲ 63.9% | 6.23M▲ 221.3% | 14.58M▲ 0% |
Free Cash Flow | -2.24M▲ 0% | -6.95M▼ 211.0% | -7.87M▼ 13.2% | -16.27M▼ 106.9% | -14.37M▲ 11.7% | -17.78M▼ 23.7% | -24.81M▼ 39.5% | -17.15M▲ 30.9% | -15.31M▲ 10.7% | -14.29M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -67.07% | -210.95% | -13.18% | -106.88% | 11.7% | -23.73% | -39.55% | 30.88% | 10.72% | 6.14% |
FCF per Share | -388.70 | -1009.27 | -981.48 | -916.18 | -610.16 | -741.50 | -906.96 | -214.05 | -16.42 | -2.06 |
FCF Conversion (FCF/Net Income) | 0.66x | 0.55x | 0.65x | 0.78x | 0.69x | 0.75x | 0.80x | 0.81x | 0.94x | 0.85x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GNPX Key Ratios
Genprex, Inc. (GNPX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -322.79% | -265.79% | -179% | -105.73% | -57.25% | -74.71% | -207.88% | -467.24% | -338.74% | -247.33% |
Return on Invested Capital (ROIC) | -1010.3% | -2202.06% | -1149.48% | -583.44% | -496.49% | -900.68% | -2331.34% | -4555.22% | -15565.84% | 3762.08% |
Debt / Equity | 0.47x | 0.01x | - | - | - | - | - | - | - | 0.00x |
Interest Coverage | -1752.56x | -324.74x | - | - | - | - | - | - | -20.93x | -35.18x |
FCF Conversion | 0.66x | 0.55x | 0.65x | 0.78x | 0.69x | 0.75x | 0.80x | 0.81x | 0.94x | 0.85x |
Related:GNPX Dividend History·GNPX Revenue History·GNPX Price History·GNPX P/E History·GNPX Financial Ratios·GNPX Institutional Holders
GNPX SEC Filings & Documents
Genprex, Inc. (GNPX) SEC filings — annual & quarterly reports (10-K, 10-Q)
GNPX Frequently Asked Questions
Genprex, Inc. (GNPX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Genprex, Inc. (GNPX) grew revenue by 0.0% over the past year. Growth has been modest.
Genprex, Inc. (GNPX) reported a net loss of $16.7M for fiscal year 2025.
Dividend & Returns
Genprex, Inc. (GNPX) has a return on equity (ROE) of -338.7%. Negative ROE indicates the company is unprofitable.
Genprex, Inc. (GNPX) had negative free cash flow of $14.3M in fiscal year 2025, likely due to heavy capital investments.